Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
FASEB J ; 34(1): 399-409, 2020 01.
Artigo em Inglês | MEDLINE | ID: mdl-31914606

RESUMO

The liver plays a key role during fasting to maintain energy homeostasis and euglycemia via metabolic processes mainly orchestrated by the insulin/glucagon ratio. We report here that fasting or calorie restriction protocols in C57BL6 mice promote a marked decrease in the hepatic protein levels of G protein-coupled receptor kinase 2 (GRK2), an important negative modulator of both G protein-coupled receptors (GPCRs) and insulin signaling. Such downregulation of GRK2 levels is liver-specific and can be rapidly reversed by refeeding. We find that autophagy, and not the proteasome, represents the main mechanism implicated in fasting-induced GRK2 degradation in the liver in vivo. Reducing GRK2 levels in murine primary hepatocytes facilitates glucagon-induced glucose production and enhances the expression of the key gluconeogenic enzyme Pck1. Conversely, preventing full downregulation of hepatic GRK2 during fasting using adenovirus-driven overexpression of this kinase in the liver leads to glycogen accumulation, decreased glycemia, and hampered glucagon-induced gluconeogenesis, thus preventing a proper and complete adaptation to nutrient deprivation. Overall, our data indicate that physiological fasting-induced downregulation of GRK2 in the liver is key for allowing complete glucagon-mediated responses and efficient metabolic adaptation to fasting in vivo.


Assuntos
Adaptação Biológica/efeitos dos fármacos , Autofagia , Jejum , Quinase 2 de Receptor Acoplado a Proteína G/metabolismo , Glucagon/farmacologia , Fígado/metabolismo , Animais , Quinase 2 de Receptor Acoplado a Proteína G/genética , Fármacos Gastrointestinais/farmacologia , Homeostase , Fígado/efeitos dos fármacos , Fígado/patologia , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Transdução de Sinais
2.
Cell Mol Life Sci ; 77(23): 4957-4976, 2020 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-31927610

RESUMO

Macrophages are key effector cells in obesity-associated inflammation. G protein-coupled receptor kinase 2 (GRK2) is highly expressed in different immune cell types. Using LysM-GRK2+/- mice, we uncover that a reduction of GRK2 levels in myeloid cells prevents the development of glucose intolerance and hyperglycemia after a high fat diet (HFD) through modulation of the macrophage pro-inflammatory profile. Low levels of myeloid GRK2 confer protection against hepatic insulin resistance, steatosis and inflammation. In adipose tissue, pro-inflammatory cytokines are reduced and insulin signaling is preserved. Macrophages from LysM-GRK2+/- mice secrete less pro-inflammatory cytokines when stimulated with lipopolysaccharide (LPS) and their conditioned media has a reduced pathological influence in cultured adipocytes or naïve bone marrow-derived macrophages. Our data indicate that reducing GRK2 levels in myeloid cells, by attenuating pro-inflammatory features of macrophages, has a relevant impact in adipose-liver crosstalk, thus preventing high fat diet-induced metabolic alterations.


Assuntos
Tecido Adiposo/metabolismo , Dieta Hiperlipídica , Quinase 2 de Receptor Acoplado a Proteína G/metabolismo , Fígado/metabolismo , Células Mieloides/metabolismo , Obesidade/metabolismo , Adipócitos/efeitos dos fármacos , Adipócitos/metabolismo , Adipócitos/patologia , Tecido Adiposo Branco/patologia , Animais , Meios de Cultivo Condicionados/farmacologia , Citoproteção/efeitos dos fármacos , Fígado Gorduroso/complicações , Fígado Gorduroso/patologia , Microbioma Gastrointestinal/efeitos dos fármacos , Glucose/metabolismo , Intolerância à Glucose/metabolismo , Hipertrofia , Inflamação/patologia , Insulina/metabolismo , Resistência à Insulina , Macrófagos Peritoneais/efeitos dos fármacos , Macrófagos Peritoneais/metabolismo , Camundongos Endogâmicos C57BL , Modelos Biológicos , Células Mieloides/efeitos dos fármacos , Obesidade/complicações , Transdução de Sinais/efeitos dos fármacos , Aumento de Peso/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA